Dentsply Sirona (NASDAQ: XRAY) stock outlook for 2026. A committed analysis of the razor-and-blade consumables base, the CEREC CAD/CAM installed base, the multi-year turnaround, discretionary equipment cyclicality, and clear-aligner competition against Invisalign.
A qualitative 2026 outlook on Wontech (KOSDAQ 336570), the Korean energy-based aesthetic device maker behind Oligio monopolar RF and Picocare picosecond lasers. We dissect the razor-blade model of device sales plus recurring tip and cartridge consumables, export expansion across Asia, Europe, the Middle East and Latin America, rivalry with Classys, Jeisys Medical and Lutronic, and the discretionary aesthetic spending risk for Korea-focused investors.
TMDX (TransMedics Group) stock outlook for 2026. A qualitative deep dive into how the OCS perfusion device replaces the ice cooler, the equipment-plus-consumables-plus-aviation model, the organ utilization thesis, and the valuation, execution, regulatory, and short-seller risks.
Hologic (NASDAQ: HOLX) stock analysis for 2026: the Panther molecular installed base and assay pull-through, 3D Genius mammography and recurring service revenue, the post-COVID normalization to a clean organic-growth base, the women's-health moat, tuck-in M&A and buybacks, plus competitive risk from Roche, BD, GE HealthCare and Siemens.
Masimo (MASI) 2026 stock outlook. A deep look at the SET pulse oximetry moat, the razor-and-blade sensor model, the Sound United misstep, the Politan activist campaign and governance reset, and the Apple Watch ITC patent win.
Insulet (PODD) stock analysis for 2026: Omnipod 5 AID momentum, type-2 diabetes expansion, pharmacy-channel growth, GLP-1 overhang debate, and competitive risks from Tandem and Medtronic.
A qualitative deep-dive into The Cooper Companies (COO) stock outlook for 2026 — CooperVision's specialty lens mix shift, MiSight myopia management, CooperSurgical fertility tailwinds, and key risks to watch.
Dexcom (DXCM) stock analysis 2026: $4.82B TTM revenue up 16.2%, EPS +75.5% to $2.34, P/E 30.8x, GLP-1 drug interaction with CGM adoption, Stelo OTC launch, FreeStyle Libre competition, and analyst consensus Strong Buy with $81.64 target.
Boston Scientific (BSX) stock analysis 2026: TTM revenue $20.6B growing 17.4%, P/E 24.2x, 52-week range $52.52–$109.50, analyst target $83.47, WATCHMAN FLX growth, and EP system competitive dynamics.
Intuitive Surgical stock analysis for 2026: da Vinci 5 FDA clearance and upgrade cycle implications, razor-and-blade model economics, Ion lung biopsy platform growth, competitive threats from Medtronic Hugo and J&J Ottava, and valuation framework for growth investors.